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ABSTRACT
Glucocorticoid (GC) therapy is themost frequent cause of secondary osteoporosis. In this study we have demonstrated that GC treatment
induced the development of autophagy, preserving osteocyte viability. GC treatment resulted in an increase in autophagy markers and
the accumulation of autophagosome vacuoles in vitro and in vivo promoted the onset of the osteocyte autophagy, as determined by
expression of autophagymarkers in an animal model of GC-induced osteoporosis. An autophagy inhibitor reversed the protective effects
of GCs. The effects of GCs on osteocytes were in contrast to tumor necrosis factor a (TNF-a), which induced apoptosis but not autophagy.
Together this study reveals a novel mechanism for the effect of GC on osteocytes, shedding new insight into mechanisms responsible for
bone loss in patients receiving GC therapy.  2010 American Society for Bone and Mineral Research.
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Introduction
Glucocorticoids (GCs) are used extensively for the treatmentof chronic inflammatory and autoimmune diseases. How-
ever, prolonged use of GCs results in reduction of bone mineral
density (BMD), with fractures occurring in 30% to 50% of patients
treated chronically with GCs.(1) Administration of GCs leads to
decreased generation of osteoblasts and osteocytes, accom-
panied by a prolonged lifespan of osteoclasts.(2) Increased
apoptosis of osteocytes and osteoblasts has been observed with
high-dose GC treatment in mice and in clinical biopsy specimens
in some, but not all, studies.(3–6) Apoptosis of osteocytes and
osteoblasts could reduce bone formation and possibly weaken
the bone structure, leading to an increase in fracture risk.
However, neither the changes in bone metabolism and bone
architecture nor the modest amount of apoptosis of osteoblasts
and osteocytes can explain the elevated bone fragility observed
in GC-treated patients.(7) We have reported increased osteocyte
lacunar size with a loss of perilacunar mineral with GC treatment,
suggesting that the osteocyte is metabolically stressed or
compromised.(8) In this model of GC treatment, less than 5% of
osteocytes were found to be apoptotic, suggesting another
effect of GCs. Therefore, the focus of this study was to determine
whether autophagy, a protective mechanism by which cells can
respond to stress, may be relevant to GC-induced changes to
osteocytes.
Autophagy is a lysosomal degradation pathway that is
essential for cell growth, survival, differentiation, development,
and homeostasis.(9) It is a tightly regulated process that helps to
maintain a balance among the synthesis, degradation, and
subsequent recycling of cellular products. During autophagy,
parts of the cytoplasm and intracellular organelles are
sequestered within autophagic vacuoles that are eventually
delivered to lysosomes for bulk degradation.(10) Autophagy has
been proposed as a ‘‘double-edged sword’’ in heart tissue.(11)
Autophagy can protect the cells from apoptosis by removing
oxidatively damaged organelles. On the other hand, excess
autophagy can destroy cellular components. Autophagy there-
fore can preserve viability or, alternatively, can be a self-
destructive process that leads to cell death.(12) However, whether
autophagy is involved in the effect of GCs on bone cells was
unknown previously.
In this study, we show that GC treatment of osteocytes and
mice resulted in the development of autophagy. Inhibition of
autophagy led to augmentation of the effect of GCs on cell
viability. Our observations offer novel findings that autophagy is
a major mechanism used by osteocytes in self-protection against
the detrimental effect of GCs that results in bone loss.
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Materials and Methods
Cell culture
MLO-Y4 cells were cultured on collagen-coated (rat tail collagen
type I, 0.15mg/mL) surfaces and were grown in phenol red–free
a-MEM supplemented with 2.5% fetal bovine serum (FBS) and
2.5% bovine calf serum (BCS) and incubated in a 5% CO2
incubator at 378C, as described previously.(13)
Isolation of chicken primary osteocytes
Preparation of primary osteocytes from chicken calvarias was
based on published procedures.(13) Briefly, calvarial bone was
dissected from 16-day-old embryonic chicks. The soft tissues and
osteoid were removed by collagenase, followed by decalcifica-
tion using EDTA. The final particles were treated with collagenase
and agitated vigorously to release osteocytes and cultured in
a-MEM supplemented with 10% FBS for 1 hour at 378C.
Cell viability assay
MLO-Y4 cells were seeded in 96-well flat-bottomed plates and
incubated overnight at 378C. After exposure to dexamethasone
(Dex) at various concentrations and times, the cells were exposed
to 10mL of WST-1 reagent for 1 to 2 hours at 378C. The absor-
bance at 450 nm was measured using a microplate reader.
Alternatively, MLO-Y4 cells were plated in a 6-well plate over-
night at 378C. After the treatment with Dex, the number of viable
cells was counted. The annexin V staining of Dex or TNF-a/CHX-
treated MLO-Y4 cells was performed using the Annexin-V-FLOUS
Staining Kit (Roche Applied Science, Indianapolis, IN, USA).
Propidium iodide (PI) staining also was performed at the same
time using the same kit.
LDH-cytotoxicity assay
A Lactate Dehydrogenase (LDH) Cytotoxicity Assay Kit (BioVision,
Mountain View, CA, USA) was used for quantification of plasma
membrane damage. MLO-Y4 cells were seeded in a 96-well plate
overnight at 378C. After treatment with Dex, the plates were
centrifuged at 250g for 10minutes. Then 100mL per well of
supernatant was transferred into corresponding wells of a clear
96-well plate and followed by addition of 100mL of the reaction
mixture to each well and incubation for 30minutes in the dark.
The absorbance at 490 nm was measured using a microplate
reader. The maximum release of LDH was determined by
incubation of the cells in 1% Triton X-100 for 1 hour in culture
medium. The percentage of cytotoxicity was determined by the
following equation: cytotoxicity (%)¼ [(test samples – blank)/
(maximum – blank)] 100.
DAPI staining for detection of chromatin condensation
MLO-Y4 cells were treated with Dex, fixed in 4% paraformalde-
hyde for 30minutes, incubated with DAPI (0.2mg/mL) for
10minutes, and examined by fluorescence microscopy.
Mitochondrial membrane potential
After treatment with Dex, cells were collected by trypsinization,
stained with 100 nM TMRE in phenol red–free a-MEM medium
without serum for 20minutes at 378C, and then analyzed with
flow cytometry.
Detection and quantification of acidic vesicular
organelles with acridine orange staining
MLO-Y4 cells were stained with acridine orange (1mg/mL) for
15minutes at 378C. For quantification of the development of
acidic vesicular organelles, the cells were stained with acridine
orange (1mg/mL) for 15minutes at 378C and measured by flow
cytometry (gate set at 5%; FACScan Flow Cytometer, BD Bio-
sciences, San Jose, CA, USA) at green (510 to 530 nm) and red
(>650 nm) fluorescence emission from 2 104 cells illuminated
with blue (488 nm) excitation light. The data were analyzed by
BD CellQuest software (San Jose, CA, USA).
Detection of autophagic vacuoles with
monodansylcadaverine (MDC)
Cells were incubated with MDC at a concentration of 0.05mM in
PBS at 378C for 10minutes. Cells then were washed four times
with PBS and analyzed by fluorescent microscopy (excitation
380 nm, emission 525 nm). Alternatively, cells were collected in
10mM Tris-HCl, pH 8.0, containing 0.1% Triton X-100, and
the supernatant was assayed on a Fluoro-Max-3 fluorometer
(Horiba Jobin Yvon, Edison, NJ, USA) (excitation 380 nm, emission
519 nm), and the intensity of the fluorescence was quantified.
GFP-LC3 dots assay
A GFP-LC3 dots assay was performed as described previously.(14)
Cells were transiently transfected with the GFP-LC3 vector. After
overnight culture, the cells were treated with Dex, fixed with 4%
paraformaldehyde, and examined under a fluorescence micro-
scope. To quantify autophagic cells after Dex treatment, cells
exhibiting GFP-LC3 punctuate dots were counted.
Histologic sections and immunocytochemistry
Six-month-old male Swiss-Webster male mice were obtained
from Charles River, Inc. (Wilmington, MA, USA) The mice were
maintained on commercial rodent chow (22/5 Rodent Diet,
Teklad, Madison, WI, USA) available ad libitum with 0.95%
calcium and 0.67% phosphate. Mice were housed in a room that
was maintained at 218C with a 12-hour light/dark cycle. Slow-
release pellets (Innovative Research of America, Sarasota, FL,
USA) of placebo or 5mg/60 day slow-release prednisolone
pellets (group 2, n¼ 15) were administrated by subcutaneous
implantation. The third lumbar vertebral body (LVB) were
decalcified in 10% EDTA for 2 weeks and embedded in paraffin.
Then 4-mm sections were collected using a Leica 2265
Microtome (Bannockburn, IL, USA). After deparaffinization and
rehydration, sections were blocked in PBS containing 1% goat
serum at room temperature for 1 hour and then labeled with
1:100 dilution of anti-LC-3 antibody for 1 hour and followed by
incubation with the ABC reagent (Vector, Burlingame, CA, USA) at
room temperature for 30minutes. Alkaline phosphatase sub-
strate solution was used to visualize immunoreaction sites.
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Gene microarray analysis
RNA was extracted from the long bones of placebo- or GC-
treated mice. Purified total RNA (10mg) from each animal (n¼ 3
to 5 per time point) was used for cDNA synthesis, which served as
a template for in vitro transcription with biotin incorporation. All
the microarray analyses were run for individual animals (n¼ 3 to
5 per group per time point) from placebo- or GC-treated groups
euthanized on days 0, 7, 28, and 56. Fragmented biotinylated
transcripts were hybridized to the Mouse Genome 430 2.0 Array
(Affymetrix, Santa Clara, CA, USA) according to the manu-
facturer’s protocol. Washing and staining of the arrays were
performed on a Fluidics Station 450 (Affymetrix), and the arrays
then were scanned using the GeneChip Scanner 3000
(Affymetrix). Raw intensity data for 45,101 probe sets were
processed and obtained from the scanned image files by the
GeneChip Operating Software (GCOS, Affymetrix).
Results
Reduction of MLO-Y4 cell number by Dex
To determine the effect of GCs on the number of osteocytic MLO-
Y4 cells, the cells were treated with various concentrations of Dex
(109 to 105 M) or ethanol alone for 6, 24, or 48 hours, and the
normal cell number was determined using WST-1 and dead cells
by trypan blue exclusion assays. Dex reduced the normal
numbers of MLO-Y4 cells in a time- and dose-dependent manner
compared with 0 time and no treatment (Fig. 1A, B). Surprisingly,
very few dead cells were detected at 24 and 48 hours using
trypan blue. We then evaluated the effect of RU486, a GC
receptor antagonist, to study the mechanistic action of GCs.(15,16)
RU486 by itself had no effect, but it significantly prevented the
effect of Dex on reducing the numbers of normal cells (Fig. 1C).
Next, PI staining and flow cytometric quantification were
performed to examine cell death (Fig. 1D). Interestingly, there
was a slight, but not significant, increase in PI staining after Dex
treatment for 6, 24, and 48 hours (approximately 2% PI staining
after 48 hours of Dex treatment), suggesting that very little cell
death was occurring. In contrast, TNF-a/CHX treatment, reagents
reported to cause apoptosis of MLO-Y4 cells,(17) lead to a
dramatic increase in PI staining and cell death. To assess the
extent of plasma membrane damage, the release of the
cytoplasmic enzyme LDH was quantified after Dex treatment
at 106 M or 105 M for 48 hours (Fig. 1E). This result shows that
there was no increase of LDH release from MLO-Y4 cells treated
with Dex. It has been reported that an insoluble hydrophobic
form of Dex in aqueous solution is more toxic for cells.(18) To
control for this potential side effect, we treated the cells with Dex
in the presence of 0.04% or 1% ethanol (Fig. 1F). Ethanol did not
exhibit any discernible effect on the number of MLO-Y4 cells.
Together these results suggest that Dex treatment resulted in
either a decrease in normal cell number or an inhibition of
proliferation of MLO-Y4 osteocytes without apparent plasma
membrane damage.
Dex induced minimal MLO-Y4 cell apoptosis
The preceding experiment indicated that apopotosis-related cell
death may not be responsible for the reduced cell number.
Therefore, we conducted several conventional assays to test for
apoptosis. MLO-Y4 cells were treated with Dex at 106 M for
24 hours and then labeled with the nuclear marker DAPI (Fig. 2A).
No significant difference in nuclear staining between control
and Dex-treated cells was observed. The cell viability also was
assessed by measuring the inner mitochondrial membrane
potential by TMRE uptake (Fig. 2B). Compared with vehicle-
treated controls (Fig. 2B, left panel, blue), TNF-a/CHX treatment
resulted in a significant shift to the left of the peak (green) in the
histogram, implying loss of mitochondrial membrane potential.
Conversely, Dex treatment for 48 hours (red) did not result in a
peak shift, suggesting that mitochondrial membrane potential
was not altered by Dex. Quantitative assessment revealed a
significant decrease in TMRE uptake by TNF-a/CHX but not by
Dex treatment (Fig. 2B, right panel). Annexin V/PI staining is a
rapid and sensitivemethod for the detection of apoptosis.(19) The
cells stained with annexin V represent two types of cell
responses. One is for cells in early apoptosis, which cannot be
stained with PI, showing that the cell membrane is not ‘‘leaking.’’
These cells are in the lower right quadrant (Fig. 2D). When cells
stain for both annexin V and PI, as shown in the upper right
quadrant, this suggests that the cell membrane is ‘‘leaky’’ or that
the cell is dead (Fig. 2D). TNF-a/CHX treatment for 10 hours
significantly increased annexin V, but no significant increase was
detected after Dex treatment for 6, 24, or 48 hours (Fig. 2C).
Quantification using fluorescence-activated cell sorting (FACS)
separation showed that TNF-a/CHX treatment for 10 hours
significantly increased the number of annexin Vþ as well as PI-
labeled cells (two right quadrants, 57.5% versus 6.5% for control),
but there was no increase in annexin V/PI labeling with Dex
treatment for 6 or 48 hours (Fig. 2D; 6 hours: 5% versus 6.7%
control; 48 hours: 9.3% versus 6.7%). Together these data show
that unlike TNF-a/CHX, Dex treatment did not induce significant
levels of apoptosis-related cell death in MLO-Y4 cells.
Dex induces autophagy in MLO-Y4 cells
Autophagy is characterized morphologically by the accumula-
tion of acidic vesicular organelles.(20) To determine if acidic
vesicular organelles occur in Dex-treated MLO-Y4 cells, acridine
orange was used. Staining of MLO-Y4 cells with acridine orange
revealed the appearance of acidic vesicular organelles (AVOs)
after Dex treatment, as visualized by a concentrated dye staining
pattern in the cytoplasmic vacuoles with bright red fluorescence
(Fig. 3A). Green fluorescence indicated nonacidic granules and
remained relatively constant. Flow cytometric analysis was
conducted to quantify acridine orange–labeled cells by using the
FL3 channel to evaluate the bright red fluorescence and the FL1
channel for green fluorescence (Fig. 3B). Dex treatment induced
a significant increase in the intensity of bright red fluorescence
from 3.4% to 16.1%. 3-MA, an inhibitor of class III phosphati-
dylinositol-3 kinase (PI3K), which is known to inhibit autophagic
sequestration,(21,22) partially suppressed the induction of auto-
phagic vacuoles in Dex-treated cells (Fig. 3B). Pretreatment with
RU486 completely reversed the stimulatory effect of Dex on
autophagy, as shown by flow cytometry (Fig. 3C). These results
suggest that the Dex-induced increase in bright red fluorescence
GLUCOCORTICOID AND AUTOPHAGY IN OSTOECYTES Journal of Bone and Mineral Research 2481
is attributable to the development of AVOs associated with
autophagy.
The presence of MDC has been used as a specific marker
for the detection of autophagic vacuoles.(23) Dex significantly
increased the accumulation of MDC compared with nontreated
control cells, and this increase was completely reversed by 3-MA
(Fig. 3D). These data suggest that Dex induces the formation
of mature autophagic vacuoles.
The expression of microtubule-associated protein light chain 3
(LC3) and the increased level of LC-3-II are important markers for
autophagy development.(21) Consistently, a time-dependent
decrease (after 12, 16 and 24 hours of Dex treatment) of the ratio
of LC3-I to LC3-II was observed in MLO-Y4 cells treated with Dex
(Fig. 4A). The further accumulation of LC3, especially LC3-II, was
observed when cells were treated with the lysosomal inhibitors
E64d and calpeptin (Fig. 4B). This result indicates that Dex-
Fig. 1. Reduction of MLO-Y4 cell number by Dex. (A, B) MLO-Y4 cells were treated with Dex at 105, 106, 107, 108, and 109 M for 0, 6, 24, and 48 hours.
The number of viable cells was measured using WST-1 or trypan blue dye exclusion assay. No or few trypan blue cells were detected. (C) Cells were
pretreated with 1 or 10mM RU486 prior to the application of Dex, and the cell number was determined usingWST-1. RU486 partially reversed the negative
effects of Dex on the number of live MLO-Y4 cells. (1 or 10mM RU486 plus Dex–treated versus only Dex-treated samples: p< .05.) (D) Cells were treated
with 106 M Dex for 6, 24, and 48 hours or with 10 ng/mL of TNF-a/CHX for 6 hours. Cell number was analyzed by PI staining, and the number of PI-labeled
cells was quantified. (TNF-a/CHX-treated versus control samples: p< .001.) (E) Cell membrane damage was measured by release of the cytoplasmic
enzyme lactate dehydrogenase (LDH) from MLO-Y4 cells treated with Dex or TNF-a/CHX. (48 hours of Dex- or TNF-a/CHX-treated versus control:
p< .001.) ( F) Cells were treated with 0.04% or 1% ethanol or Dex dissolved in 0.04% or 1% ethanol, and cytotoxicity was determined usingWST-1 assay.
All data are presented as mean  SD and n¼ 3.
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induced upregulation of autophagy is facilitated primarily
through biosynthesis but not through the blockage of LC3-II
degradation.(24)
GFP-tagged LC3 has been used as a sensitive method to
demonstrate the induction of autophagy.(21,25,26) MLO-Y4 cells
that expressed GFP-LC3 showed a diffuse distribution of green
fluorescence in the absence of Dex. In contrast, treatment with
Dex increased the number of ‘‘dots’’ or a punctate pattern and
also fluorescence intensity (Fig. 4C, left panel), indicating that LC3
was recruited and aggregated on the membrane during Dex-
induced autophagy. Quantification of these data suggests that a
significantly increased number of Dex-treated cells exhibited the
aggregation of LC3 compared with untreated cells (approxi-
mately 16% versus 6%). Western blot also showed the increase in
GFP-LC3-II level by Dex treatment (Fig. 4D). Thin-section electron
microscopic analysis showed the accumulation of membranous
vesicles with cellular contents (solid arrowheads) in Dex-treated
cells, but such structures were barely detectable in vehicle-
treated control cells (Fig. 4E). Collectively, these results suggest
that Dex-induced autophagy inMLO-Y4 cells was associated with
induction as well as processing of LC3-I to LC3-II involved in the
formation of autophagosomes.
To further validate the development of autophagy in
osteocytes, we used primary osteocytes isolated from chicken
calvaria (Fig. 5A). Similar to our observation in MLO-Y4 cells, Dex
treatment significantly increased autophagy, indicated by red
fluorescence with acridine orange staining (Fig. 5A, right panel),
and this increase was significantly inhibited by 3-MA (Fig. 5A,
right panel).
The development of autophagy also was observed in
osteocytes in mice treated with prednisolone (5mg, 60-day
slow-release pellet) for 2 months (Fig. 5B). LC3þ cells (red-brown
staining, arrowheads) were visible in osteocytes of prednisolone-
treated (Fig. 5B, panels c and d) but not in those of control mice
(panels a and b), suggesting that autophagy by GCs occurs in
osteocytes in vivo. Using gene microarray analysis, we found
that the messenger levels of several autophagy markers,
including LC-3a, LC-3b, autophagy-related 16 like 2, and
autophagy-related 7, were elevated in bone samples of mice
under chronic prednisolone treatment (Fig. 5C). Remarkably,
compared with placebo (PL) control, the most dramatic increase
occurs after 28 days of the GC treatment, whichmay indicate that
a self-preservation mechanism was active during this time
period.
Fig. 2. The major effects of Dex on MLO-Y4 cell number is not due to induced cell apoptosis. (A) MLO-Y4 cells were treated in the absence or presence
of 106 M Dex for 48 hours and then labeled with DAPI. (B) Cells were treated with 106 M Dex or TNF-a/CHX for 48 hours, and suspended cells were
stained with 100 nM TMRE and analyzed using flow cytometry and quantified (right panel). (TNF-a/CHX versus control and Dex-treated: p< .001.)
(C) MLO-Y4 cells treated in the absence or presence of 106 M Dex for 6, 24, and 48 hours or TNF-a/CHX for 10 hours, labeled with Annexin-V-FLOUS
Staining Kit and PI. (D) After treatment with 106 M Dex for 6 and 48 hours or TNF-a/CHX for 10 hours, detached and attached cells were analyzed using
flow cytometry.
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Inhibition of autophagy leads to a further reduction of
normal cell numbers in response to Dex
To determine whether autophagy is involved with the effects
of Dex on osteocytes, we cotreated MLO-Y4 cells with Dex and
3-MA (Fig. 6). Increasing concentrations of 3-MA resulted in
reduced numbers of cells measured by WST-1, suggesting that
autophagy plays a role in maintaining cell survival under control
conditions. More important, the reduction in the number of cells
by Dex was significantly augmented by 3-MA at 200 nM
and 1mM, suggesting that autophagy plays a critical role in
protecting the cells from the effects of Dex.
Discussion
GCs are effective anti-inflammatory and autoimmune modulat-
ing agents, but GC treatment alters bone metabolism and
increases bone fragility and subsequent bone fractures. We have
shown that autophagy could be a major mechanism by which
the osteocyte responds to elevated GCs. GC treatment resulted
in a significant increase in markers of autophagy both in vitro
and in vivo. GC treatment decreased the number of MLO-Y4
osteocytes in vitro, but no significant cell death was observed.
Moreover, when autophagy was inhibited, a further decrease
in metabolically normal cell number was observed with GC
treatment. Together, our study suggests that autophagy is a
likely self-protective process in osteocytes in response to the
insult of GCs.
A previous study reported that GCs induce apoptosis of
osteocytes, reporting nearly 15% to 20% apoptotic cells in GC-
treated mice.(3) Interestingly, Lane and colleagues(8) reported
increased osteocyte lacunar size and loss of mineral around the
osteocytes, suggesting that a metabolic change had occurred in
the presence of GC treatment. Very few apoptotic cells were
observed. This led us to determine whether another mechan-
ism(s) such as autophagy could be occurring in osteocytes that
may account for the localized osteocyte perilacunar changes
observed with GC treatment. By using multiple cell viability
assays, we found that Dex reduced the number of osteocytes by
over 50%. However, we did not detect significant levels of cell
death, as determined by trypan blue and PI staining, consistent
Fig. 3. Induction of autophagy in MLO-Y4 cells by Dex. (A) Dex induced the development of autophagy. MLO-Y4 cells were treated in the absence or
presence of 106 M Dex for 48 hours and labeled with acridine orange. (B) Cells were treated with 106 M Dex for 48 hours in the absence or presence of
0.5mM 3-MA. 3-MA was added 1 hour prior to Dex treatment. Cells in suspension were labeled with acridine orange and quantified using flow cytometry
(gate set at 5%), and the data were analyzed by CellQuest software. FL1-H indicates green color intensity (cytoplasm and nucleus), whereas FL3-H shows
red color intensity (AVO). (C) Cells were treated with 106 M Dex for 48 hours in the absence or presence of 10mMRU486. The latter was added 1 hour prior
to Dex. Acridine orange–labeled cells in suspension were quantified using flow cytometry. (D) Cells were treated with 106 M Dex for 48 hours in the
absence or presence of 0.5mM 3-MA. 3-MA was added 1 hour prior to Dex treatment. Cells then were labeled with MDC, and the intensity of the staining
was quantified by measuring fluorescence in cell lysate using a fluorometer. (Dex-treated versus others: p< .05.) The data are presented as mean SD
and n¼ 3.
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with other GC studies.(8,27) It has been postulated that GC
receptor binding to mitochondrial membranes may regulate
membrane potential and integrity. However, using TMRE dye, we
failed to observe any alteration in the mitochondrial membrane,
indicating that mitochondrial dysfunction was not induced by
GCs under our experimental conditions. In partial agreement
with our findings, others have reported that a small number of
apoptotic cells are generated in response to GCs.(28)
We detected increased autophagic activity induced by Dex.
Several standard approaches were adopted to determine
autophagy based on recently published guidelines,(20) including
fluorescent GFP-LC3 dots, MDC fluorescence, LC3 lipidation,
and electron microscopic imaging, in addition to conventional
acridine orange staining. The enhancement of autophagy also
was validated in isolated primary osteocytes and osteocytes in
bone from mice chronically treated with prednisolone. In
addition, our gene microarray study showed the increased
messenger level of several autophagy markers in the bone of
the mice under GC treatment. The most dramatic elevation of
autophagy markers was observed after 28 days of treatment.
Interestingly, gene markers for proapoptosis, as well as
osteoblast and osteocyte apoptosis, were not increased signi-
ficantly until a later stage (56 days of chronic GC exposure).(8,29)
Gene markers for autophagy were highly correlated with the
gene markers for matrix proteolysis, including matrix metallo-
proteases (MMPs), caspases, and cathepsins.(29) The increased
Fig. 4. Dex increased LC3 levels and autophagosome development. (A) MLO-Y4 cells were treated with or without 106 M Dex for the indicated times and
then subjected to immunoblotting analysis using anti-LC3 or anti-b-actin antibody. The band intensity was quantified, and the ratio of LC3-I/LC3-II was
presented at the bottom of the blot. (B) Cells were treated with or without 106 M Dex for 24 hours in the absence or presence of E64d (10mg/mL) or
calpeptin (10mg/mL). The latter two reagents were added 1 hour prior to Dex. The band intensity was quantified, and the ratio of LC3-I/LC3-II was
presented at the bottom of the blot. (C) Cells were transiently transfected with GFP-LC3 construct for 24 hours, then treated with or without 106 M Dex for
an additional 24 hours, and then examined by fluorescence microscopy. The percentage of GFP-LC3þ cells with GFP-LC3 punctate dots was quantified by
counting the number of cells showing the punctate pattern of LC3-GFP in 100 GFPþ cells. (Dex versus control: p< .05.) The data are presented as
mean SD and n¼ 3. (D) Cells were treated with 106 M Dex for 24 hours after being transiently transfected with GFP-LC3 construct for 24 hours. Cell
lysates were analyzed by Western blot. The band intensity was quantified, and the ratio of LC3-I/LC3-II was presented at the bottom of the blot. (E) Cells
were treated with 106 M Dex for 24 hours, and fixed cells were processed for thin-section electron microscopy. M indicates mitochondrial structures, and
arrowheads indicate autophagosomes.
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osteocytic autophagy and matrix proteolysis, in return, might
induce the demineralization around the osteocytes that over
time may weaken whole-bone strength.(8)
Autophagy was suppressed by 3-MA, which supports the
hypothesis that Dex activates the autophagosomal pathway.
More important, 3-MA, which blocks autophagy, actually
enhanced the number of dead cells with GC treatment. In
contrast to 3-MA, RU486 completely inhibited autophagy but
partially rescued the reduction of viable cell numbers by Dex.
One possible explanation is that RU486 is an antagonist of GC
receptors that abolished any effects exerted by Dex, including
autophagy induced by Dex. The rescue of cell number by RU486
is mainly due to the lack of Dex effect, which may not be directly
related to the autophagy at all. 3-MA, on the other hand, may
suppress autophagy activity directly. These data suggest that the
increased autophagy is a likely self-responsive mechanism by
osteocytes toward attenuating the effect of Dex on osteocytes.
Autophagy, like a ‘‘double-edged sword,’’ has been reported to
be involved in both cell protection and cell death.(11,12) It
depends on the cell type and the level and duration of the stress.
A unique feature of autophagy is that it is a protective
mechanism against cell death probably initially or under short or
moderate stress conditions. Our cell viability study showed that
under our treatment regime, autophagic cells are very much
alive and are likely under certain metabolic stress. Autophagy
may be a mechanism whereby osteocytes can repair damaged
organelles or cell membranes, such as in response tomicrocracks
in pathologic overload. However, higher, persistent stress may
generate a large accumulation of autophagosomes, leading to
cell death. Indeed, apoptotic tunnel–positive osteocytes and
Fig. 5. GCs increased markers of autophagy in primary osteocytes and in osteocytes within bone tissues from GC-treated mice. (A) Primary osteocytes
isolated from chicken calvaria were treated with or without 106 Dex for 48 hours in the absence or presence of 3-MA (0.5mM). 3-MA was added 1 hour
before Dex treatment. Cells then were labeled with acridine orange, and green and red fluorescence was detected in acridine orange–stained cells using a
fluorescence microscope (left panel). The staining intensity of acridine orange in the acquired images was quantified with NIH ImageJ analysis software
(right panel). About 100 cells per sample were analyzed and normalized to control. (Red fluorescence in Dex-treated cells versus other treatment: p< .01;
p< 0.05.) The data are presented as mean SD and n¼ 3. (B) Mice were treated with 5mg of prednisolone for 60 days (prednis) (c and d) or with placebo
(controls) (a and b). Paraffin sections were immunolabeled with anti-LC3 antibody, followed by incubation with AP-linked anti-rabbit secondary antibody,
and counterstained with methyl-green. Arrowheads indicate LC3-labeled osteocytes. (C) RNA was extracted from the long bones of placebo- or
prednisolone (prednis)–treated mice, gene microarray was conducted, and raw data were processed. Transcripts related to autophagy are increased after
prednisolone treatment.
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osteoblasts are increased in vertebral cancellous bone of mice
treated with 56 days of prednisolone.(3,30) Therefore, long-term
treatment with GCs leads to cell death and, consequently, a
reduction in bone strength and bone loss. Future studies are
required to fully unravel the detailed mechanisms regulating the
development and progression of autophagy in response to GC
treatment.
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